...
【24h】

Bioactivity of microporous borate glass-ceramics prepared from solution and derived glasses

机译:从溶液和衍生眼镜制备的微孔硼酸盐玻璃陶瓷的生物活性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Microporous borate compositions based on the formula xB(2)O(3)center dot(100-x)(0.5CaO center dot 0.45Na(2)O center dot 0.05P(2)O(5)) (x = 56.1 and 51.1 mol%) have been prepared from solution. The dried products were subjected to heat-treatment at 600 and 700 degrees C for 3 h to obtain borate glass-ceramics with scaffold-like structure. Bioactivity and degradation were tested in simulated body fluid (SBF) at 37 degrees C for different time intervals. Scanning (SEM) and transmission (TEM) electron microscopy, infrared spectroscopy (FTIR) and X-ray diffraction (XRD) were used to examine the correlation between bioactivity and microstructure. Results indicated that the type and concentration of crystalline CaNaB5O9 and CaNa3B5O10 phases, in addition to concentration of bridging and non-bridging oxygen atoms, are the factors affecting the apatite forming ability and composition degradation. XRD and SEM results showed that the as-prepared compositions and those heat-treated at 600 and 700 degrees C are crystalline matrices, while TEM-EDP of selected region exhibited halo diffuse intensity with clear bright spots. These features indicate that the crystalline phases are dispersed in amorphous phase. After immersion in SBF, TEM-EDP proved that the crystalline hydroxyapatite (HA) phase was formed on amorphous phase. The type of product after reaction in SBF is influenced by the nature of borate network. For melt-derived borate glasses, hydrous species of B(OH)(3) and amorphous calcium phosphate are formed. Microporous borate glass-ceramics exhibited a good in vitro bioactive response through the formation of hydroxyapatite, except when the matrix is rich in CaNa3B5O10 phase. The results of this study suggest that the solution-method can be used to prepare microporous bioactive borate glass-ceramics, such as three-dimensional porous scaffolds, which are of particular interest for the clinical application in bone regeneration.
机译:从溶液中制备了基于式xB(2)O(3)中心点(100-x)(0.5CaO中心点0.45Na(2)O中心点0.05P(2)O(5))(x=56.1和51.1 mol%)的微孔硼酸盐组合物。干燥后的产品在600和700℃下热处理3小时,以获得具有支架状结构的硼酸盐微晶玻璃。在37℃的模拟体液(SBF)中,以不同的时间间隔测试生物活性和降解。扫描(SEM)和透射(TEM)电子显微镜、红外光谱(FTIR)和X射线衍射(XRD)用于研究生物活性与微观结构之间的相关性。结果表明,结晶相CaNaB5O9和CaNa3B5O10的类型和浓度,以及桥联和非桥联氧原子的浓度,是影响磷灰石形成能力和成分降解的因素。XRD和SEM结果表明,所制备的成分以及在600和700℃下热处理的成分为晶体基质,而所选区域的TEM-EDP显示出光晕扩散强度和清晰的亮点。这些特征表明,晶相分散在非晶相中。浸泡在SBF中后,TEM-EDP证明结晶羟基磷灰石(HA)相是在非晶相上形成的。SBF反应后产物的类型受硼酸盐网络性质的影响。对于熔融衍生的硼酸盐玻璃,形成含水的B(OH)(3)和无定形磷酸钙。微孔硼酸盐微晶玻璃通过形成羟基磷灰石表现出良好的体外生物活性反应,但基质富含CaNa3B5O10相时除外。本研究结果表明,溶液法可用于制备具有生物活性的微孔硼酸盐微晶玻璃,如三维多孔支架,这对骨再生的临床应用特别有意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号